Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Webinars

Don’t miss your chance to engage with industry thought-leaders on topics that matter in taking drugs from ideas to the clinic.

Upcoming Webinars


A Tale of Two Libraries: how can complementary collections drive success in lead identification?

Dr Louise Birch, Principal Scientist, Computational Chemistry

Weds 28 April, 3pm (UK)

High-throughput screening (HTS) can be an efficient means to rapidly identify promising compounds. However the quality and diversity of the libraries screened ultimately determines the number and value of the hits. The ability to perform fast follow up on those hits allows rapid expansion of the active pool, aiding early understanding of structure-activity relationships and prioritisation of resources.

REGISTER FOR THIS WEBINAR


The Many Facets of Early Phase Evaluation of Psychedelics in Psychiatry – A Roadmap to Studying Safety, Abuse Potential, and Efficacy

Joint webinar with Dr Beatrice Setnik (Altasciences) and Dr Sharon Cheetham (Sygnature Discovery)

Thurs 20 May, 4pm (UK)

There are a number of psychiatric disorders with high unmet clinical need where psychadelics are increasingly being looked to as a potential therapy. Psychedelics have established human abuse potential, and many are Schedule I Controlled Drugs (CDs), i.e. not approved for medical use. Therefore the production, distribution and supply is tightly controlled and regulated. Supporting regulatory approvals for medical use requires safety and efficacy evaluations. For psychedelics in development, regulatory approval will require a shift from Schedule I CD, to a CD schedule for medical use. In this webinar we will discuss the clinical and non-clinical studies required for evaluation of abuse risks of psychadelic drugs. Data for the various types of psychedelics in pre-clinical drug-discrimination, intravenous self-administration and physical dependence models will be presented. We will review the regulatory guidance and offer advice on how these studies can be designed to meet the expectations of FDA, and other regulatory agencies. We will also review safety studies and early examinations of efficacy that can help guide drug development decisions for later phase patient trials.

REGISTER FOR THIS WEBINAR


Past Webinars

Mouse Models of Cancer: understand their limitations to exploit their strengths

VIEW WEBINAR

To Control or be Controlled: Navigating the abuse potential evaluation of CNS-active drugs for EU and US submissions

VIEW WEBINAR

How DMPK should integrate with and influence projects in discovery and beyond

VIEW WEBINAR

Rethinking Diabetes Drug Discovery

VIEW WEBINAR

Can we improve oncology drug discovery?

VIEW WEBINAR

Can rodent kidney models really simulate the clinic?

VIEW WEBINAR

How to choose the best biophysical technique for your project

VIEW WEBINAR

Decision making in abuse potential assessments… are we getting it right?

VIEW WEBINAR

A journey through anti-inflammatory drug discovery

VIEW WEBINAR

How we created a world-leading HTS system

VIEW WEBINAR